Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 63, Issue 8, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00399-19
Keywords
Aspergillus; anidulafungin; calcineurin; caspofungin; heat shock protein 90; ibrexafungerp; micafungin; paradoxical effect; rezafungin
Categories
Funding
- Swiss National Science Foundation (SNSF Ambizione-Score) [PZ00P3 161140]
- Santos-Suarez Foundation
- Swiss National Science Foundation (SNF) [PZ00P3_161140] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Echinocandins (caspofungin, micafungin, anidulafungin), targeting beta-1,3-gluon synthesis of the cell wall, represent one of the three currently available anti fungal drug classes for the treatment of invasive fungal infections. Despite their limited antifungal activity against Aspergillus spp., echinocandins are considered an alternative option for the treatment of invasive aspergillosis (IA). This drug class exhibits several advantages, such as excellent tolerability and its potential for synergistic interactions with some other antifungals. The objective of this review is to discuss the in vitro and clinical efficacy of echinocandins against Aspergillus spp., considering the complex interactions between the drug, the mold, and the host. The antifungal effect of echinocandins is not limited to direct inhibition of hyphal growth but also induces an immunomodulatory effect on the host's response. Moreover, Aspergillus spp. have developed important adaptive mechanisms of tolerance to survive and overcome the action of echinocandins, such as paradoxical growth at increased concentrations. This stress response can be abolished by several compounds that potentiate the activity of echinocandins, such as drugs targeting the heat shock protein 90 (Hsp90)-calcineurin axis, opening perspectives for adjuvant therapies. Finally, the present and future places of echinocandins as prophylaxis, monotherapy, or combination therapy of IA are discussed in view of the emergence of pan-azole resistance among Aspergillus fumigatus isolates, the occurrence of breakthrough IA, and the advent of new long-lasting echinocandins (rezafungin) or other beta-1,3-glucan synthase inhibitors (ibrexafungerp).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available